Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date

By D. Bobo, Kye J. Robinson, Jiaul Islam, K. Thurecht, S. Corrie. Pharmaceutical Research, 2016

2,232 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Materials Chemistry

View Paper: https://www.semanticscholar.org/paper/50673eb604fa3df6091e30583a2a5567f155f0be

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. F. Danhier
2. Daniel G. Anderson
3. V. Préat
4. H. Tran
5. K. El-Say
6. Hossam S. El-Sawy
7. Robert Langer
8. Shoujun Xu

In Biomedical Engineering

1. F. Danhier
2. Daniel G. Anderson
3. K. El-Say
4. Hossam S. El-Sawy
5. Robert Langer
6. Pragati Jamdagni
7. J. S. Rana
8. T. Randall Lee

In Materials Chemistry

1. H. Tran
2. K. El-Say
3. Hossam S. El-Sawy
4. Pragati Jamdagni
5. Shoujun Xu
6. J. S. Rana
7. Minh Dang Nguyen
8. T. Randall Lee

Citations in the corpus

• Green synthesis of zinc oxide nanoparticles using flower extract of Nyctanthes arbor-tristis and their antifungal activity (2016, background): “Also, inhibitory effects of ZnO nanosuspension are correlated with their size and concentration, with smaller particles offering better inhibitions in higher concentrations (Buzea et al., 2007; Padmavathy and Vijayaraghavan, 2008).”
• Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review (2018, background): “Therefore, an accord among researchers, industry and regulatory authorities is necessary to overcome these barriers [301,302].”
• Polymeric nanoparticles: Promising platform for drug delivery. (2017, background): “Eligard (Tolmar), Macugen (Bausch & Lomb), Pegasys (Genentech), PegIntron (Merck) and many other products which is PNPs elaborated products and FDA approved are many years ago already in the market with very satisfying outcomes (Bobo et al., 2016).”
• Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer (2018, background): “According to the literature, the FDA has approved few gold nanoparticle-based technologies for diagnostic and therapeutic purposes in medicine [55,68].”
• Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine (2019, background): “However, before the premarket authorization, nanocarriers are subject to a range of preclinical and clinical validation by regulatory agencies, such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the USA.”
• Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures (2017, background): “Rienso that caused several serious fatal hypersensitivity cases and long-term kidney disease) [67].”